- Home
- / Foghorn Therapeutics
Foghorn Therapeutics
Stock Price
$4.3
2023-11-27
Market Capitalization
$183.6 M
2023-11-27
Revenue
$19.2 M
FY, 2022
Foghorn Therapeutics Summary
Company Summary
- Overview
- Foghorn Therapeutics is a developer of gene therapies for hematologic cancers and solid tumors. Through its Gene Traffic Control platform, the company studies, identifies, and validates potential drug targets within the chromatin regulatory system.
- Type
- Public
- Status
- Active
- Founded
- 2016
- HQ
- Cambridge, MA, US | view all locations
- Website
- http://www.foghorntx.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Samuel Agresta, Chief Medical Officer
Fanny Cavalié, Senior Vice President, Business and Operations
Steve Bellon, Senior Vice President , Drug Discovery, Vice President, Drug Discovery
Operating MetricsView all
Discovery Stage Products
3
Q2, 2020
IND-Enabling Stage Products
2
Q2, 2020
LocationsView all
2 locations detected
Cambridge, MA HQ
United States
NE47, 500 Technology Square #700
Cambridge, MA
United States
100 Binney St #610
Foghorn Therapeutics Financials
Summary Financials
- Revenue (Q3, 2023)
- $17.5M
- Net income (Q3, 2023)
- ($14.3M)
- Cash (Q3, 2023)
- $70.3M
- EBIT (Q3, 2023)
- ($17.1M)
- Enterprise value
- $160.4M